High-Dose Mizoribine Treatment for Adolescents with Systemic Lupus Erythematosus

This study found that mycophenolate mofetil is effective for both induction and maintenance therapy in children with severe lupus nephritis, significantly improving proteinuria and antibody levels, without renal flares during maintenance.

This study found that mycophenolate mofetil was associated with higher response rates and lower rates of serious side effects, including a lower mortality rate, compared to cyclophosphamide in lupus nephritis treatment.

This review update suggests that mycophenolate mofetil may increase complete disease remission in proliferative lupus nephritis compared to intravenous cyclophosphamide, but with low certainty of evidence.

This study reports that Rituximab may be a safe and effective treatment for refractory juvenile systemic lupus erythematosus complicated by macrophage activation syndrome, allowing for successful steroid tapering.

This review discusses recent adult studies on systemic lupus erythematosus treatments and explores their implications for pediatric cases, emphasizing a critical need for more pediatric-focused research.